Komori
Governance4591RIBOMIC Inc.Pharmaceuticals

Notice Regarding Officer Appointments Associated with the Transition to a Company with an Audit and Supervisory Committee

Subject to approval at the General Meeting of Shareholders scheduled for 23 June 2026, the Company plans to transition from a company with a Board of Corporate Auditors to a company with an Audit and Supervisory Committee. In connection with the transition, 3 directors serving as Audit and Supervisory Committee members will be newly appointed, while 1 incumbent director and 3 corporate auditors will retire.

Worth reading
84Important
Scored from 3 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Governance structure

The Company currently has a Board of Corporate Auditors. Subject to approval at the 23rd Annual General Meeting of Shareholders scheduled for 23 June 2026, it plans to transition to a company with an Audit and Supervisory Committee.
Number of directors7 director candidates after the transition, including 5 outside directors
Number of independent officers3Number

This is the number of people reported to the exchange as independent officers. Whether someone is an outside officer and whether they qualify as independent are separate determinations.

Committee1
Nomination and Compensation Committee. The proportion of outside members is not disclosed
Changes this time

The Company plans to transition from a company with a Board of Corporate Auditors to a company with an Audit and Supervisory Committee. 3 directors serving as Audit and Supervisory Committee members will be nominated as new candidates, while 1 director and 3 corporate auditors are scheduled to retire.

Governance structure
ItemDetails
Corporate Governance StructureThe Company currently has a Board of Corporate Auditors. Subject to approval at the 23rd Annual General Meeting of Shareholders scheduled for 23 June 2026, it plans to transition to a company with an Audit and Supervisory Committee.
Number of directors7 director candidates after the transition, including 5 outside directors
Number of independent officers3 independent officers: Matsufuji Senya (松藤千弥), Fujiwara Toshinobu (藤原俊伸), and Nishihata Toshiaki (西畑利明). Yamamoto Mamoru (山本守) and Kaiami Makoto (貝阿彌誠) are scheduled to be reported as independent officers after their appointment.
CommitteeNomination and Compensation Committee. The proportion of outside members is not disclosed
Changes this timeThe Company plans to transition from a company with a Board of Corporate Auditors to a company with an Audit and Supervisory Committee. 3 directors serving as Audit and Supervisory Committee members will be nominated as new candidates, while 1 director and 3 corporate auditors are scheduled to retire.
Items this document does not state (3)
Policy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company has determined the director candidates to be proposed to the General Meeting of Shareholders as part of the officer appointments accompanying the transition to a company with an Audit and Supervisory Committee. This document does not explain the reason for the transition itself.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Officer Appointments Associated with the Transition to a Company with an Audit and Supervisory Committee | RIBOMIC Inc. (4591) timely disclosure | Komori